Analyst Group

Analyst Group Comment on Circio’s In Vivo CAR-M Collaboration with United Immunity

Källa: MFN
Neutral

Sammanfattning

Circio Holding ASA har inlett ett forskningssamarbete med United Immunity för att utvärdera circVec i kombination med United Immunitys leveransplattform för in vivo CAR-M terapi. Samarbetet syftar till att utveckla en gemensam plattform för behandling av cancer, fibros och autoimmuna sjukdomar. Inga finansiella villkor har offentliggjorts.

Analys

Samarbetet med United Immunity ses som en tekniskt välgrundad utveckling för Circios portfölj inom in vivo cellterapi. De kombinerade teknologierna adresserar kompletterande utmaningar inom leverans och uttryck, vilket potentiellt kan skapa en differentierad CAR-M plattform. Även om CAR-M-området befinner sig i ett tidigt prekliniskt stadium och inga finansiella villkor har presenterats, stärker samarbetet CircVecs långsiktiga licensieringsattraktivitet, särskilt med tanke på stora läkemedelsbolags investeringar inom fältet.

Insikter

  • • Analyst Group har mottagit ersättning för att publicera denna kommentar.
  • • Företaget har inte haft möjlighet att påverka Analyst Groups subjektiva bedömningar.

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 26th of March 2026, that the Company has entered a research collaboration with United Immunity Co., Ltd. (”United Immunity”), a Tokyo-based biotechnology company, to evaluate circVec in the context of in vivo CAR-Macrophage (CAR-M) therapy. Under the collaboration, United Immunity will test whether its proprietary P-LNP delivery platform can deliver circVec to myeloid immune cells, specifically macrophages and dendritic cells, with the aim of establishing a joint platform for in vivo CAR-M applications in cancer, fibrosis, and autoimmune disorders. No financial terms have been disclosed.

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 26th of March 2026, that the Company has entered a research collaboration with United Immunity Co., Ltd. (”United Immunity”), a Tokyo-based biotechnology company, to evaluate circVec in the context of in vivo CAR-Macrophage (CAR-M) therapy. Under the collaboration, United Immunity will test whether its proprietary P-LNP delivery platform can deliver circVec to myeloid immune cells, specifically macrophages and dendritic cells, with the aim of establishing a joint platform for in vivo CAR-M applications in cancer, fibrosis, and autoimmune disorders. No financial terms have been disclosed.

In summary, Analyst Group views the United Immunity collaboration as a meaningful and technically well-founded addition to Circio’s in vivo cell therapy portfolio. The two technologies address complementary bottlenecks, United Immunity solving the delivery problem, circVec the expression problem, and together could form the basis of a differentiated CAR-M platform. While no financial terms have been disclosed and the CAR-M space remains at an early preclinical stage, Analyst Group regards the collaboration as a longer-term optionality layer that incrementally strengthens circVec’s long-term licensing attractiveness, particularly in light of large pharmaceutical players committing multi-billion dollar capital to the in vivo cell therapy field.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.